

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Drug classes not included on this list are not managed through a Preferred Drug List (PDL).
HOWEVER, THIS EXCLUSION IS NOT A GUARANTEE OF PAYMENT OR COVERAGE. Dosage limits and other requirements may apply.
Drugs new to market are non-preferred until a clinical review has been completed. PA criteria will apply to both the pediatric population,
as well as the adult population for those plans where PA/PDL limits are allowed.
Unless otherwise noted on the PDL, generic substitution is mandatory.

Yellow highlighted items below indicate new changes to the PDL. Red font indicates quantity/dosage limits apply. *Indicates BRAND is Preferred. May Use DAW 5.
Contact the Change Healthcare PA Helpdesk @ 877-207-1126 for prior authorization if client has primary insurance that will not cover the brand name medication.

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.**

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>PLEASE CONTACT CHANGE HEALTHCARE WITH ANY QUESTIONS</small>
ADDICTION	BUPRENORPHINE COMBINATIONS		Client must have a diagnosis of opioid dependence or abuse. This is not to be used for the treatment of chronic pain. Prescriber must have a XDEA number. Prior authorization will be required before any narcotic, benzodiazepine, or carisoprodol prescription will be allowed between fills. Prior authorization will be required before any short-acting stimulant prescription from any doctor other than the prescriber of buprenorphine or Suboxone, will be allowed between fills. Oral buprenorphine will be approved for clients that are pregnant or nursing or with a documented allergy to naloxone. Please submit PA requests on the "Oral Buprenorphine/Naloxone or Oral Buprenorphine" PA form available at www.wymedicaid.org . Dosage limits apply During first two years of treatment: 16mg After two years of treatment: 8mg	BUNAVAIL buprenorphine (oral) buprenorphine/naloxone tablets (use preferred) ZUBSOLV
		SUBOXONE FILM		
	NALTREXONE		Client must have a diagnosis of alcohol or opioid dependence. Prior authorization will be required before any narcotic, carisoprodol, or benzodiazepine prescription will be allowed between fills. Prior authorization will be required before a short-acting stimulant prescription from any doctor other than the prescriber of naltrexone or Vivitrol will be allowed between fills.	
		naltrexone VIVITROL		
ALLERGY / ASTHMA	ANTI-HISTAMINES, MINIMALLY SEDATING		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	desloratadine CLARINEX RDT/SYRUP levocetirizine
	cetirizine fexofenadine loratadine			
	ANTI-HISTAMINE/DECONGESTANT COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	CLARINEX-D
	cetirizine/pseudoephedrine fexofenadine/pseudoephedrine loratadine/pseudoephedrine			
	ANTICHOLINERGIC BRONCHODILATORS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Spiriva 5 day STARTER package will be allowed one (1) time per recipient.	ATROVENT HFA INCRUSE ELLIPTA SEEBRI SPIRIVA RESPIMAT (use preferred agent) TUDORZA
	ipratropium SPIRIVA HANDHALER			
	INHALED COMBINATION AGENTS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. **Will also require the diagnosis of COPD. ***Will also require the diagnosis of COPD or uncontrolled asthma. Advair 7 and 14-day STARTER package will be allowed one (1) time per recipient.	ANORO ELLIPTA** BEVESPI BREO ELLIPTA*** COMBIVENT DULERA fluticasone/salmeterol 232,113,55-14mcg STIOLTO TRELEGY UTIBRON
	ADVAIR DISK/HFA SYMBICORT			
	LEUKOTRIENE MODIFIERS		Trial and failure of preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	zafirlukast ZYFLO
	montelukast			
LONG ACTING BRONCHODILATORS		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. **Arcapta will require a diagnosis of COPD and the client must be older than 40 years of age	ARCAPTA** PERFORMIST STRIVERDI	
BROVANA FORADIL SEREVENT				
NASAL ANTIHISTAMINES		Trial and failure of preferred agent greater than or equal to 90 days in the last 12 months will be required before approval can be given for a non-preferred agent.	azelastine 0.15% AZENASE (use separate agents) DYMISTA (use separate agents) olopatadine 0.6%	
ASTELIN* azelastine 0.1%				
NASAL STEROIDS		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Budesonide will be approved for pregnancy.	AZENASE (use separate agents) budesonide DYMISTA (use separate agents) mometasone (BRAND IS PREFERRED) OMNARIS QNASL TICANASE (use separate agents) triamcinolone VERAMYST ZETONNA	
BECONASE AQ flunisolide fluticasone NASONEX*				
SHORT ACTING BRONCHODILATORS - INHALERS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Minimum day supply of at 16 days is required	PROAIR RESPICLIC XOPENEX HFA*	
PROAIR HFA PROVENTIL HFA VENTOLIN HFA				

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

Therapeutic Class	Preferred Agents	Preferred Agents Requiring Clinical Criteria	Clinical Criteria	Non-Preferred Agents Generic Mandatory Policy Applies <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PHARMACEUTICAL SUPPLIER WITH ANY QUESTIONS</small>		
ALLERGY / ASTHMA continued	SHORT ACTING BRONCHODILATORS - NEBULIZERS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.			
	albuterol neb levalbuterol neb					
	STERIOD INHALANTS		Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Alvesco will be approved for a history of oral thrush with steroid inhalants.	AEROBID/AEROBID-M AEROSPAN ALVESCO ARMONAIR ARNUITY ASMANEX budesonide susp 0.25mg, 0.5mg, and 1mg (BRAND IS PREFERRED) QVAR/REDIHALER		
	EPINEPHRINE			ADRENALCLICK (use preferred agent) AUVI-Q (use preferred agent) EPI-PEN (use preferred agent)		
ARTHRITIS	IMMUNOMODULATORS		Client must have diagnosis of AS prior to approval of a step 1 agent (Enbrel or Humira). To receive Cosentyx, the client must have a diagnosis of AS and a 56-day trial and failure of Humira. To receive a non-preferred agent, client must have a diagnosis of AS and a 56-day trial and failure of both preferred agents Quantity Limits apply for all diagnoses: Enbrel 25mg - limited to 10 per month Enbrel 50mg - limited to 5 per month Humira 20mg - limited to 10 per month Humira 40mg - limited to 5 per month	CIMZIA REMICADE (additional criteria applies) SIMPONI		
	ANKYLOSING SPONDYLITIS (AS)					
	STEP 1 AGENTS					
		ENBREL HUMIRA				
	STEP 2 AGENTS					
		COSENTYX				
	JUVENILE IDIOPATHIC ARTHRITIS (JIA)				Client must have diagnosis of JIA prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of JIA and a 56-day trial and failure of both preferred agents.	ACTEMRA ORENCIA
	ENBREL HUMIRA					
	PSORIATIC ARTHRITIS (PA)				Client must have diagnosis of PA prior to approval of a step 1 agent (Enbrel or Humira). To receive Cosentyx, the client must have a diagnosis of PA and a 56-day trial and failure of Humira. To receive a non-preferred agent, client must have a diagnosis of PA and a 56-day trial and failure of both preferred agents	CIMZIA ORENCIA OTEZLA REMICADE (additional criteria applies) SIMPONI
	STEP 1 AGENTS					
	ENBREL HUMIRA					
STEP 2 AGENTS						
	COSENTYX					
RHEUMATOID ARTHRITIS (RA)		Client must have diagnosis of RA and a 56-day trial and failure of methotrexate prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of RA and a 56-day trial and failure of both preferred agents.	ACTEMRA CIMZIA KEVZARA KINERET ORENCIA REMICADE (additional criteria applies) RITUXAN SIMPONI XELJANZ/XR			
	ENBREL HUMIRA					
CONVULSIONS	DIAZEPAM RECTAL GEL			diazepam gel (BRAND IS PREFERRED)		
	DIASTAT*		Limited to FDA approved indications			
CROHN'S	ORAL ANTICONVULSANTS					
		APTIOM FYCOMPA VIMPAT				
CROHN'S	IMMUNOMODULATORS		Client must have diagnosis of Crohn's prior to approval of the preferred agent. To receive a non-preferred agent, client must have a diagnosis of Crohn's and a 56-day trial and failure of the preferred agent.	CIMZIA REMICADE (additional criteria applies) STELARA TVSABRI (additional criteria applies)		
		HUMIRA				
DERMATOLOGY	IMPETIGO ANTIBIOTICS		Trial and failure of ALL preferred agents greater than or equal to 7 days in the past 90 days. Use smallest size appropriate for 7 day trial.			
	gentamicin mupirocin					
	BENZOYL PEROXIDE/ADAPALENE COMBOS			adapalene/benzoyl peroxide gel 0.1-2.5% (BRAND IS PREFERRED)		
	EPIDUO*					
	BENZOYL PEROXIDE/CLINDAMYCIN COMBOS		Clients must be 12 to 20 years of age and have a diagnosis of acne vulgaris. Requires prior authorization for clients less than 12 years of age. Acne combinations are limited to clients under the age of 21.	ACANYA (use preferred agent) clindamycin/benzoyl peroxide 1-5% (BRAND IS PREFERRED) ONEXTON (use preferred agent)		
		BENZACLIN* clindamycin/benzoyl peroxide 1.2-5% (Refrig)				
	CORTICOSTEROIDS - STEP 1 AGENTS C=CREAM; G=GEL; L=LOTION; O=OINTMENT		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	PANDEL prednicarbate 0.1% (C,O) TEXACORT 2.5% (S)		
	LOW POTENCY					
	alclometasone desonide DESOWEN 0.05% (L) fluocinolone 0.01% hydrocortisone butyrate 0.1% (C) hydrocortisone 1%, 2.5% (C,L,O) SYNALAR 0.01%					
	MEDIUM POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	Clocortolone Pivalate CORDRAN/SP fluticasone 0.05% (L) hydrocortisone butyrate 0.1% (O) TOPICORT LP TRIANEX		
betamethasone valerate CUTIVATE 0.05% (C) DERMATOP 0.1% (C) desoximetasone 0.05% (C) ELOCON 0.1% fluocinolone 0.025% fluticasone 0.05% (C) hydrocortisone probutate 0.1% (C) mometasone SYNALAR 0.025% TOPICORT 0.05% (C) triamcinolone 0.025%, 0.1%						

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.							
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PHARMACEUTICAL REPRESENTATIVE WITH ANY QUESTIONS</small>			
DERMATOLOGY continued	HIGH POTENCY		Trial and failure of ALL preferred agents greater than or equal to 14 days in the last 90 days.	APEXICON aminconide 0.1% (C,L,O) augmented betamethasone 0.05% (G,L,O) clobetasol 0.05% (L) desoximetasone 0.05%, 0.25% (C,G,O) fluocinonide 0.1% (C) HALOG			
	betamethasone dipropionate clobetasol/E 0.05% (C,G,O,S) diflorasone DIPROLENE 0.05% (L) fluocinonide flurandrenolide fluticasone 0.005% (O) halobetasol TEMOVATE/E TOPICORT 0.25% (C) triamcinolone 0.5% ULTRAVATE 0.05%						
	IMMUNOMODULATORS - STEP 2 AGENTS				To receive a step 2 agent: Trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial and a trial and failure of a preferred high potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days. For clients less than two (2) years of age, a trial and failure of a preferred low potency corticosteroid greater than or equal to a 21 day trial and a trial and failure of a preferred medium potency topical corticosteroid greater than or equal to a 21 day trial in the last 90 days.		
		ELIDEL tacrolimus ointment					
	PHOSPHODIESTERASE 4 INHIBITOR - STEP 3 AGENT					To receive a step 3 agent: Trial and failure of a preferred step 2 agent (immunomodulator) greater than or equal to a 21 day trial within the last 30 days.	
	PLAQUE PSORIASIS (PP)						
	STEP 1 AGENTS						
	ENBREL HUMIRA						
	STEP 2 AGENTS						
	COSENTYX TREMFYA						
	SALICYLIC ACID						All other topical salicylic acid formulations.
	salicylic acid cream 6% salicylic acid lotion 6% salicylic acid shampoo 6%						
SCABICIDES/PEDICULICIDES		Trial and failure of a preferred agent in the last 12 months.					
NATROBA permethrin SKLICE							
UREA			All other topical urea formulations.				
ALUVEA CREAM 33% UMECTA EMULSION umecta mousse aerosol 40% urea lotion 40% urea lotion 45%							
DIABETES AGENTS				metformin SR 24HR osmotic release (use preferred agent) metformin SR 24HR modified release (use preferred agent) RIOMET (use preferred agent)			
BIGUANIDES							
metformin/ER							
α-GLUCOSIDASE INHIBITORS					Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.		
acarbose							
MEGLITINIDES						repaglinide	
nateglinide							
THIAZOLIDINEDIONES							Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.
pioglitazone							
SULFONYLUREAS		Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.					
glimepiride/ER glipizide/ER glyburide/ER							
DIIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS			Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.				
JANUVIA							
DPP-4 INHIBITOR COMBO AGENTS				Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.			
JANUMET/XR							
INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)					Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.		
BYETTA VICTOZA							
DIABETES AGENTS						metformin SR 24HR osmotic release (use preferred agent) metformin SR 24HR modified release (use preferred agent) RIOMET (use preferred agent)	
BIGUANIDES							
metformin/ER							
α-GLUCOSIDASE INHIBITORS							Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.
acarbose							
MEGLITINIDES		repaglinide					
nateglinide							
THIAZOLIDINEDIONES			Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.				
pioglitazone							
SULFONYLUREAS				Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.			
glimepiride/ER glipizide/ER glyburide/ER							
DIIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS					Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.		
JANUVIA							
DPP-4 INHIBITOR COMBO AGENTS						Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	
JANUMET/XR							
INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)							Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.
BYETTA VICTOZA							
DIABETES AGENTS		metformin SR 24HR osmotic release (use preferred agent) metformin SR 24HR modified release (use preferred agent) RIOMET (use preferred agent)					
BIGUANIDES							
metformin/ER							
α-GLUCOSIDASE INHIBITORS			Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.				
acarbose							
MEGLITINIDES				repaglinide			
nateglinide							
THIAZOLIDINEDIONES					Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.		
pioglitazone							
SULFONYLUREAS						Trial and failure of metformin and a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
glimepiride/ER glipizide/ER glyburide/ER							
DIIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS							Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.
JANUVIA							
DPP-4 INHIBITOR COMBO AGENTS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.					
JANUMET/XR							
INCRETIN MIMETICS (GLP-1 RECEPTOR AGONISTS)			Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.				
BYETTA VICTOZA							

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PROVIDER WITH ANY QUESTIONS</small>
DIABETES continued	SGLT2 INHIBITORS		Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent. A 90 day trial of failure of the preferred agent is required before approval can be give for a non-preferred agent.	GLYXAMBI (use separate preferred agents) INVOKAMET/XR(use separate preferred agents) INVOKANA QTERN (use separate preferred agents) SYNJARDY/XR (use separate preferred agents) XIGDUO XR (use separate preferred agents)
		FARXIGA JARDIANCE		
	LONG-ACTING INSULIN		Prior authorization will be required when using two different delivery forms of the same type of insulin concurrently	LANTUS OPTICLIK (use preferred agent) TOUJEO (use preferred agent) TRESIBA (use preferred agent) XULTOPHY (use preferred agent)
	LANTUS SOLOSTAR LANTUS vial LEVEMIR			
DIABETIC METERS/TEST STRIPS		Quantity limits apply: Insulin Dependent Clients: 10 strips/day Non-Insulin Dependent Clients: 4 strips/day Clients are limited to 1 meter/365 days	ALL OTHER METERS AND TEST STRIPS	
FREESTYLE FREESTYLE INSULINX FREESTYLE LITE FREESTYLE FREEDOM LITE FREESTYLE PRECISION NEO ONE TOUCH ULTRA 2 ONE TOUCH ULTRA BLUE ONE TOUCH ULTRA MINI ONE TOUCH VERIO ONE TOUCH VERIO FLEX ONE TOUCH VERIO IQ PRECISION XTRA				
FIBROMYALGIA	FIBROMYALGIA STEP 1			
	amitriptyline cyclobenzaprine			
	FIBROMYALGIA STEP 2		Trial and failure of a Step 1 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 2 agent.	
	SAVELLA			
FIBROMYALGIA STEP 3		Trial and failure of a Step 1 agent and a Step 2 agent greater than or equal to six (6) weeks in the last 12 months is required for approval of a Step 3 agent. Dosage Limits Apply: Lyrica: 600mg/day		
	duloxetine LYRICA			
GASTROINTESTINAL	DIGESTIVE ENZYMES		Prior authorization required.	PANCREAZE pancrelipase PERTZYE TRI-PASE ULTRESA VIOKASE
	CREON ZENPEP			
	PREGNANCY INDUCED NAUSEA/VOMITING			
	DICLEGIS			
	CHRONIC IDIOPATHIC CONSTIPATION		Client must have a diagnosis of chronic idiopathic constipation to receive a preferred agent. To receive a non-preferred agent, the client must have a diagnosis of chronic idiopathic constipation and a 30-day trial and failure of a preferred agent within the last 12 months.	TRULANCE
		AMITIZA LINZESS		
	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION		Client must have a diagnosis of Irritable Bowel Syndrome (IBS) with constipation.	
		AMITIZA LINZESS		
	OPIOID-INDUCED CONSTIPATION AGENTS		Client must have a diagnosis of opioid-induced constipation and a three (3) month trial and failure of a secretory agent to receive the preferred agent. To receive the non-preferred agent, the client must have a diagnosis of opioid-induced constipation, a three (3) month trial and failure of a secretory agent, and a three (3) month trial and failure of the preferred agent. *Movantik will be approved for a diagnosis of cancer or for clients in hospice or palliative care.	MOVANTIK*
		AMITIZA		
PROTON PUMP INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Lansoprazole solutabs will be approved for children less than or equal to 8 years of age.	ACIPHEX SPRINKLES amox/clarith/lanso pack (use separate agents) DEXILANT esomeprazole 24.65mg and 49.3mg NEXIUM* omeprazole 20.6mg capsules (use preferred agent) omeprazole tablets (use preferred agent) omeprazole/sodium bicarbonate OMECLAMOX (use separate agents) PREVACID solutabs rabeprazole VIMOVO (use separate agents)	
lansoprazole capsules omeprazole capsules pantoprazole				
MESALAMINE		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	APRISO ASACOL HD CANASA DELZICOL GIAZO mesalamine DR tab 1.2gm (BRAND IS PREFERRED) SFLOWASA	
LIALDA* mesalamine enema PENTASA				
GOUT	COLCHICINE			COLCRYS (use preferred agent) MITIGARE (use preferred agent)
	colchicine			
XANTHINE OXIDASE AND URAT1 INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 60 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. *Concurrent use of a preferred agent will be required with Zurampic.		ZURAMPIC*
allopurinol ULORIC				

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PROVIDER WITH ANY QUESTIONS</small>
HEMATOLOGY	LOW MOLECULAR WEIGHT HEPARIN (LMWH)		Prior authorization will be required for the 300mg/3ml strength.	FRAGMIN (<i>use preferred agent</i>) LOVENOX 300MG/3ML*
	enoxaparin			
	DIRECT THROMBIN INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation and relative contraindication to warfarin for approval, treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE), or for the reduction in the risk of recurrence of DVT and PE after initial therapy.	
		PRADAXA		
	FACTOR XA INHIBITOR		Limited to being used for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE	
		BEVVYXA		
	SELECTIVE FACTOR XA INHIBITOR		Client must have diagnosis of non-valvular atrial fibrillation, treatment for deep vein thrombosis (DVT) prophylaxis in knee or hip replacement, treatment of DVT and pulmonary embolism (PE), and for the reduction in the risk of recurrent DVT and PE after initial therapy.	SAVAYSA (<i>use preferred agent</i>)
		ELIQUIS XARELTO		
	THIENOPYRIDINE DERIVATIVES		Prior authorization required for clients on antiplatelet therapy greater than one (1) year.	
	clopidogrel EFFIENT ticlopidine			
	CPTP DERIVATIVES		Prior authorization is required.	BRILINTA
PAR-1 ANTAGONIST		Client must have diagnosis of reduction of thrombotic cardiovascular events with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). Must be used in conjunction with aspirin or clopidogrel.		
	ZONTIVITY			
ANTIHEMOPHILIC FACTOR VIII			NOVOEIGHT (<i>requires prior authorization</i>)	
ADVATE ADYNOVATE AFSTYLA ELOCTATE HELIXATE FS HEMOPIL M KOATE/KOATE-DVI KOGENATE FS/BIO-SET KOVALTRY MONOCLATE-P NUWIQ OBIZUR RECOMBINATE XYNTHA/SOLOFUSE				
ANTIHEMOPHILIC FACTOR/VWF				
ALPHANATE HUMATE-P WILATE				
HEPATITIS C	DIRECT ACTING ANTIVIRALS		Limited to FDA approved indication. Prior authorization will be required prior to use of preferred agents.	DAKLINZA (<i>use preferred agent</i>) OLYSIO (<i>use preferred agent</i>) SOVALDI (<i>use preferred agent</i>) TECHNIVIE (<i>use preferred agent</i>) VIEKIRA PAK/XR (<i>use preferred agent</i>) ZEPATIER (<i>use preferred agent</i>)
		EPCLUSA HARVONI MAVYRET** VOSEVI**	**Positive SVR 12 will be required for consideration for retreatment Please submit PA requests on the Hepatitis C PA form available at www.wymedicaid.org .	
HIDRADENITIS SUPPURATIVA	IMMUNOMODULATORS		Humira will not be covered as a first line agent for the diagnosis for hidradenitis suppurativa.	
		HUMIRA		
HORMONES	GROWTH HORMONE		PA is required for use outside of FDA-approved indications. Evaluation by an endocrinologist is preferred. Clinical evidence of improved growth will be required on a yearly basis to support ongoing utilization. Clinical evidence of need for growth hormone will be required for adult growth hormone deficiency and pediatric growth failure due to inadequate endogenous growth hormone. Trial and failure of two (2) preferred agents within the last 12 months will be required for the following indications: Pediatric: Growth failure due to inadequate endogenous growth hormone, Prader-Willi syndrome, children born small for gestation, Turner syndrome. Adult: Replacement for those with growth hormone deficiency.	HUMATROPE OMNITROPE SAIZEN SEROSTIM TEV-TROPIN ZORBITIVE
		GENOTROPIN NORDITROPIN NUTROPIN AQ		
	PROGESTIN		Prior authorization is required.	
		MAKENA		
	TESTOSTERONE TOPICAL GELS		Testosterone agents are only allowed for diagnosis of hypogonadism or insufficient testosterone production. <i>Other testosterone dosage form products will require a diagnosis of hypogonadism or insufficient testosterone production (not outlined on PDL).</i>	NATESTO NASAL GEL (<i>use preferred agent</i>) TESTIM GEL (<i>use preferred agent</i>) testosterone gel 1% (BRAND IS PREFERRED) testosterone gel 2% (<i>use preferred agent</i>) VOGELXO GEL (<i>use preferred agent</i>)
		ANDROGEL*		

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PHARMACEUTICAL REPRESENTATIVE WITH ANY QUESTIONS</small>
HORMONES continued	<p style="text-align: center;">ORAL CONTRACEPTIVES</p> altavera alyacen 1-35, 7/7/7 amethyst azurette apri aubra aviane balziva bekyree blisovi 1-20 FE/24, 1.5-30 FE briellyn camila caziant chateal cyclafem 1-35, 7/7/7 cyred cryselle dasetta 1-35, 7/7/7 debilitane delyla DESOGEN deso/ethinyl estradiol elinest emoquette enpresse enskyce errin estarvlla falmina FEMCON FE CHEWABLE gianvi gildagia gildess 1-20/FE/24, 1.5-30/FE heather jencycla jolessa jolivette juleber junel 1-20/FE/24, 1.5-30/FE kariva kelnor kimidess kurvelo larin 1-20/FE/24, 1.5-30/FE leena lessina levonest levonor/ethi levora lomefia 24 FE LOSEASONIQUE* low-ogestrel lutera lyza marlissa microgestin 1-20/FE/24, 1.5-30/FE MODICON mono-linyah mononessa myzila NECON 0.5-35, 1-35, 7/7/7, 10/11-28 nora-be norgest/ethinyl estradiol norethindrone norlyroc noreth/ethin 1-20/FE/24 NORINYL 1/50-28 nortrel 0.5-35, 1-35, 7/7/7 ocella OGESTREL orsythia ORTHO TRI-CYCLEN LO* ORTHO-NOVUM 1/35, 7/7/7* philith pimtrea pirmella 1-35, 7/7/7 portia previfem reclipson SEASONIQUE* setlakin sprintec sharobel sronyx syeda tilla FE tri-estaryll tri-legest FE tri-linyah trinessa TRI-NORINYL* tri-previfem tri-sprintec trivora velivet vestura vienna viorele vyfemla wera 0.5-35 YAZ zarah zenchent ZOVIA			amethia/LO (BRAND IS PREFERRED) aranelle (use preferred agent) ashlyna (BRAND IS PREFERRED) BEVAZ (PA required) BREVICON (use preferred agent) camrese/LO (BRAND IS PREFERRED) daysee (BRAND IS PREFERRED) drosipir/ethi (use preferred agent) estarylla tri-lo (BRAND IS PREFERRED) FALESSA KIT (use preferred agent) introvale (use preferred agent) layolis FE chewable (PA required) levonorgest/ethinyl estrad (91-Day) levonorgest/ethinyl estradiol (Continuous) (use preferred agent) levonorgest/ethinyl estradiol/LO (84-7) (BRAND IS PREFERRED) LO LOESTRIN (PA required) LO MINASTRIN FE (PA required) loryna (use preferred agent) MINASTRIN 24 FE CHEWABLE (PA required) NATAZIA (PA required) norgest/ethi estradiol lo (BRAND IS PREFERRED) NATAZIA (PA required) NECON 1/50-28 (use preferred agent) nikki (use preferred agent) noreth/ethin FE chewable (PA required) NORINYL 1/35 (use preferred agent) ouasense (use preferred agent) QUARTETTE (PA required) SAFYRAL (PA required) tri-lo sprintec (BRAND IS PREFERRED) trinessa lo (BRAND IS PREFERRED) wymzya FE chewable (BRAND IS PREFERRED) zenchent FE chewable (BRAND IS PREFERRED)

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PHARMACEUTICAL MANUFACTURER WITH ANY QUESTIONS</small>	
HYPERLIPIDEMIA	BILE ACID SEQUESTRANT		Trial and failure of ALL preferred agents greater than or equal to six (6) months in the last 12 months will be required before approval can be given for a non-preferred agent.	WELCHOL	
	cholestyramine/light colestipol				
	STATINS, LOW POTENCY		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	fluvastatin/ER	
	lovastatin pravastatin				
	STATINS, HIGH POTENCY			Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. If client's current medication therapy is contraindicated with the preferred statin(s) due to a drug-drug interaction, a non-preferred agent may be obtained with a prior authorization. Prior authorization will be required for clients under the age of 10.	LIVALO rosuvastatin
atorvastatin simvastatin					
STATIN COMBINATIONS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Prior authorization will be required for clients under the age of 10.	amlodopine/atorvastatin (BRAND IS PREFERRED) ezetimibe-simvastatin (BRAND IS PREFERRED)		
	CADUET* VYTORIN*				
TRIGLYCERIDE LOWERING AGENTS		Trial and failure of a preferred agent greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ANTARA fenofibric fenofibrate 43. 50. 120. 130. and 150me LIPOFEN omega-3-acid VASCEPA		
fenofibrate 48, 54, 67, 134, 145, 160, and 200mg gemfibrozil					
HYPERTENSION	ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)		Non-preferred ARBs will require a history of ALL preferred ARBs before approval can be given.	candesartan eprosartan 600mg TEVETEN 400mg	
	EDARBI irbesartan losartan olmesartan telmisartan valsartan				
	ARBs AND DIURETICS		Non-preferred ARB/diuretic combinations will require a history of ALL preferred ARBs before approval can be given.	candesartan HCTZ telmisartan HCTZ TEVETEN HCTZ	
	EDARBYCLOR irbesartan HCTZ losartan HCT olmesartan HCTZ valsartan HCTZ				
ALPHA-BLOCKERS				clonidine patch (BRAND IS PREFERRED) NEXICLON XR (use preferred agent)	
	CATAPRES PATCHES* clonidine				
INFECTIOUS DISEASE	QUINOLONES			FACTIVE moxifloxacin NOROXIN PROQUIN	
	ciprofloxacin/ER levofloxacin ofloxacin				
	DOXYCYCLINE			ADOXA (use preferred agent) DORYX (use preferred agent) ORACEA (use preferred agent)	
	doxycycline			SOLODYN (use preferred agent)	
	MINOCYCLINE				
	minocycline/ER				
	INHALED TOBRAMYCIN		*Tobi Podhaler requires a 28 day trial of a preferred agent, as well as 28 days off of that same preferred agent prior to approval.	inhaled tobramycin (use preferred agent)	
BETHKIS KITABIS	TOBI PODHALER*				
KEFLEX		Minimum day supply of at 56 days is required	cephalexin 750mg (BRAND IS PREFERRED)		
KEFLEX 750mg*					
ANTI-RETROVIRALS					
DESCOVY EVOTAZ GENVOYA NORVIR ODEFSEY PREZCOBIX					
INFLAMMATION	NSAIDs		Trial and failure of two (2) preferred agents each greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Dosing and quantity limits apply for ketorolac (limit 5days/34 days; max dose 40mg/day for oral tablets).	CALDOLOR (use preferred agent) CAMBIA POWDER (use preferred agent) celecoxib diclofenac 1.5% solution (additional criteria applies) diclofenac 3% gel (additional criteria applies) fenoprofen FLECTOR (additional criteria applies) mefenamic acid NEOPROFEN (use preferred agent) SPRIX (additional criteria applies) TIVORBEX (use preferred agent) VIVLODEX (use preferred agent) VOLTAREN* (additional criteria applies) ZIPSOR (use preferred agent) ZORVOLEX (use preferred agent)	
	diclofenac tablets etodolac flurbiprofen ibuprofen indomethacin ketoprofen ketorolac meclofenamate meloxicam nabumetone naproxen oxaprozin piroxicam sulindac tolmetin				
ORAL CORTICOSTEROIDS				CELESTONE (use preferred agent)	
budesonide cortisone acetate dexamethasone/intensol hydrocortisone methylprednisone prednisolone prednisone					

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT CHANGE HEALTHCARE WITH ANY QUESTIONS</small>
INSOMNIA	NON-BENZODIAZEPINES		<p>Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>Prior authorization will be required for clients under the age of 18.</p> <p>Rozerem is non-preferred without a history of substance abuse</p> <p>Prior authorization will be required when a client is taking more than one insomnia agent concurrently.</p> <p>Dosage limits apply: zaleplon: 30mg/day zolpidem: 15mg/day</p>	<p>BELSOMRA EDLUAR (<i>additional criteria applies</i>) eszopiclone INTERMEZZO (<i>additional criteria applies</i>) ROZEREM zolpidem ER ZOLPIMIST (<i>additional criteria applies</i>)</p>
	zaleplon zolpidem			
MENTAL HEALTH	ALZHEIMER AGENTS		<p>Client must have a diagnosis of dementia.</p> <p>Trial and failure of two (2) preferred agents greater than or equal to six (6) weeks WITHIN THE LAST 2 YEARS will be required before approval can be given for a non-preferred agent. One of the trials of preferred agents must be in the same class (NaSS, NDRI, SSRI, or SNRI) as the requested non-preferred agent.</p> <p>Trazodone, buspirone, fluvoxamine, MAO inhibitors, TCA's, bupropion IR, and venlafaxine IR do not require prior authorization but will not count towards meeting preferred therapy requirements.</p> <p>Clients will not be allowed to be on more than one antidepressant, including fluvoxamine, bupropion IR, and venlafaxine IR, at one time with the exception of mirtazapine or bupropion with a SSRI or SNRI.</p> <p>**Duloxetine will be approved for clients with a diagnosis of osteoarthritis of the knee or chronic low back pain.</p> <p>***Trintellix requires trial and failure of two preferred agents in any class</p> <p>Clients five (5) years of age and younger will require prior authorization before approval.</p> <p>Dosage limits apply: bupropion ER/SR/XL: 450mg/day citalopram < 60 years of age: 60mg/day citalopram > 60 years of age: 30mg/day escitalopram: 30mg/day fluoxetine < 18 years of age: 90mg/day fluoxetine > 18 years of age: 120mg/day mirtazapine: 67.5mg/day paroxetine IR/CR < 18 years of age: 75mg/day paroxetine IR > 18 years of age: 90mg/day paroxetine CR > 18 years of age: 112.5mg/day sertraline: 300mg/day venlafaxine ER: 337.5mg/day</p>	<p>donepezil 23mg (<i>use preferred agent</i>) rivastigmine patches (BRAND IS PREFERRED) NAMENDA XR NAMZARIC (<i>use separate agents</i>)</p>
	ANTIDEPRESSANTS			
	NORADRENERGIC/SPECIFIC SEROTONERGICS (NaSS)			
	mirtazapine 15, 30, and 45mg			
	NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITORS (NDRI)			
	bupropion ER/SR/XL			
	SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI)			
	citalopram escitalopram fluoxetine capsules paroxetine IR/CR sertraline			
	SEROTONIN/NORPINEPHRINE REUPTAKE INHIBITORS (SNRI)			
	venlafaxine ER capsules			
ATYPICAL ANTIPSYCHOTICS		<p>**Quetiapine doses less than 100mg will require prior authorization without a diagnosis of mood disorder or major depressive disorder. For titration doses, contact the Change Healthcare Pharmacy Help Desk for an override.</p> <p>Clients five (5) years of age and younger will require prior authorization before approval.</p> <p>**Trial and failure of two (2) preferred agents greater than or equal to 30 days in the last 12 months will be required before approval can be given for REXULTI or VRAYLAR.</p> <p>***Clients twelve (12) years of age and younger will require a prior authorization to receive approval of Latuda.</p> <p>Dosage limits apply: aripiprazole <13 years of age: 23mg/day aripiprazole ≥13 years of age: 45mg/day FANAPT: 36mg/day INVEGA: 18mg/day LATUDA 13-17 years of age: 120mg/day LATUDA >17 years of age: 240mg/day olanzapine <13 years of age: 15mg/day olanzapine ≥13 years of age: 30mg/day quetiapine <13 years of age: 600mg/day quetiapine 13-17 years of age: 900mg/day quetiapine >17 years of age: 1200mg/day risperidone ≤ 17 years of age: 5mg/day risperidone >17 years of age: 24mg/day SAPHRIS: 30mg/day ziprasidone ≤17 years of age: 180mg/day ziprasidone >17 years of age: 300mg/day</p>	<p>aripiprazole ODT (BRAND IS PREFERRED) paliperidone (BRAND IS PREFERRED) REXULTI* quetiapine XR (<i>use preferred agent</i>) VRAYLAR**</p>	
ABILIFY MAINTENA ABILIFY ODT* aripiprazole tab/solution ARISTADA FANAPT paliperidone INVEGA SUSTENNA/TRINZ LATUDA*** olanzapine quetiapine RISPERDAL CONSTA risperidone SAPHRIS ziprasidone ZYPREXA RELPREVV				
SPECIAL ATYPICAL ANTIPSYCHOTICS				
clozapine/ODT				

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS <small>GENERIC MANDATORY POLICY APPLIES THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT CHANGE MANAGER WITH ANY QUESTIONS</small>
MENTAL HEALTH continued	AMPHETAMINES		Clients over the age of 17 must have a diagnosis for ADD, ADHD, (see ADD/ADHD criteria below), narcolepsy, obstructive sleep apnea, shift work sleep disturbance, MS fatigue (see MS Fatigue criteria below), or refractory depression (see refractory depression criteria below).	AMPHETAMINES
	LONG ACTING AMPHETAMINES			ADZENYS XR ODT/ER SUSP DYNAVEL VYVANSE CHEWABLES ZENZEDI 2.5 AND 7.5MG TABLETS
	amphetamine salts combo XR dextroamphetamine CR caps VYVANSE CAPSULES**		For clients over the age of 17, they must meet the DSM-5 criteria for diagnosis of ADHD. These criteria include:	
	IMMEDIATE RELEASE AMPHETAMINES			<ul style="list-style-type: none"> • Five or more symptoms of inattention, present for at least 6 months, inappropriate for developmental level; or • Five or more symptoms of hyperactivity and impulsivity, present for at least 6 months, to an extent that is disruptive and inappropriate for developmental level.
	amphetamine salts combo dextroamphetamine tablets		<ul style="list-style-type: none"> • Symptoms must be present in two or more settings (home, school or work); and • There must be clear evidence that the symptoms interfere or reduce the quality of social, school or work functioning; and • The symptoms must not be better explained by another mental disorder. 	
	METHYLPHENIDATES			Diagnosis of MS fatigue will require a fatigue severity scale score of 5.0, a 60-day trial of amantadine and discontinuation of medications that may contribute to drowsiness and fatigue.
	LONG ACTING METHYLPHENIDATES		Diagnosis of refractory depression will require a 6-week trial and failure of an antidepressant (monotherapy) and continued concomitant use of an antidepressant with the stimulant.	APTENSIO XR COTEMPLA dexamethylphenidate ER (BRAND IS PREFERRED) methylphenidate ER/CR/SR capsules (METADATE CD/RITALIN LA) QUILLICHEW QUILLIVANT XR SUSPENSION
	DAYTRANA FOCALIN XR* methylin ER methylphenidate ER/CR/SA/SR tablets***			Prior Authorization will be required for clients under the age of 4.
	IMMEDIATE RELEASE METHYLPHENIDATES		**Vyvanse will be approved for the diagnosis of binge-eating disorder for clients 18 years of age and older. Authorizations will be approved for 12 weeks, and further use of Vyvanse for this diagnosis will require additional documentation prior to approval.	
	dexmethylphenidate		Claims will require Prior Authorization if clients have a history of the following: glaucoma, cardiac arrhythmias, arteriosclerosis, untreated hypertension, untreated hyperthyroidism, substance abuse, or current MAO inhibitor use.	
	SELECTIVE ALPHA-ADRENERGIC AGONIST		Trial and failure of two (2) preferred agents (each from a different class: methylphenidate and amphetamine) greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	
	clonidine		Dosage limits apply: amphetamine salts combo XR: 60mg/day amphetamine salts combo: 60mg/day amphetamine salts combo (narcolepsy): 90mg/day DAYTRANA: 45mg/9 hour patch/day dextroamphetamine: 90mg/day dextroamphetamine CR: 90mg/day dexmethylphenidate: 30mg/day FOCALIN XR < 13 years of age: 45mg/day FOCALIN XR > 13 years of age: 60mg/day methylin/methylphenidate/ER: 90mg/day VYVANSE: 105mg/day	
	SELECTIVE ALPHA-ADRENERGIC AGONIST		To obtain the non-preferred agent , client must meet the following criteria:	KAPVAY*
			Client must have a diagnosis of ADD or ADHD	
			Prior authorization will be required for clients under the age of 4.	
			To receive Kapvay, clients must have completed a 14 day trial of clonidine IR with <u>benefit</u> in the previous 12 months.	

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR SPECIALIST WITH ANY QUESTIONS</small>
MENTAL HEALTH continued	GUANFACINE AGENTS		To obtain the non-preferred agent , client must meet the following criteria: Client must have a diagnosis of ADD or ADHD Prior authorization will be required for clients under the age of 4. To receive guanfacine ER, clients in the previous 12 months must have: A) a trial and failure of a stimulant greater than or equal to a 14 day supply, or B) a trial and failure of Strattera greater than or equal to a 30 day supply, or C) a contraindication to ADHD medications (including stimulant and non-stimulant), or D) a diagnosis of a TIC disorder, AND E) a 14 day trial of guanfacine with benefit	guanfacine ER
		SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR atomoxetine		
MIGRAINE	naratriptan RELPAK sumatriptan	TRIPHTANS	Trial and failure of two preferred agents will be required for approval of a non-preferred agent. Rizatriptan will be approved for clients between 6 and 17 years of age Quantity limits apply: naratriptan 1mg: 25 tabs/34 days naratriptan 2.5mg: 10 tabs/34 days RELPAK 20mg: 20 tabs/34 days RELPAK 40mg: 14 tabs/34 days sumatriptan vials: 2 vials/34 days sumatriptan nasal: 6 bottles/34 days sumatriptan 25mg: 41 tabs/34 days sumatriptan 50mg: 20 tabs/34 days sumatriptan 100mg: 10 tabs/34 days	almotriptan frovatriptan ONZETRA (use preferred agent) rizatriptan TREMIMET ZEMBRACE (use preferred agent) zolmitriptan
MULTIPLE SCLEROSIS	STEP 1 MS AGENTS		Trial and failure of one injectable preferred agent will be required before approval can be given for the step 2 MS agent (Gilenya). Trial and failure of two preferred agents (each from a separate class) will be required before approval can be given for a non-preferred agent. *Ocrevus will be approved for a diagnosis of primary progressive multiple sclerosis. For relapsing forms of multiple sclerosis, the requirements listed above will need to be followed For Tysabri, in addition to the above criteria, additional prior authorization criteria applies.	AUBAGIO COPAXONE 40MG/ML (use preferred agent) EXTAVIA LEMTRADA OCREVUS* PLEGRIDY TECFIDERA TYSABRI (additional criteria applies) ZINBRYTA
	IMMUNOMODULATOR (GLATIRAMER INJECTION)			
	COPAXONE 20MG/ML			
	INTERFERON AVONEX BETASERON REBIF			
	STEP 2 MS AGENTS			
	GILENYA			
NEUROPATHIC PAIN	TRICYCLIC ANTIDEPRESSANTS		For the diagnosis of neuropathic pain, trial and failure of a tricyclic antidepressant greater than or equal to a 12 week supply AND trial and failure of gabapentin at a dose of 3600mg per day for greater than or equal to a 12 week supply in the last 12 months will be required before approval can be given for a non-preferred agent.	duloxetine LYRICA
		amitriptyline desipramine imipramine nortriptyline		
	GABAPENTIN			
	gabapentin			

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT OURSHE SUPPORT WITH ANY QUESTIONS</small>
OPHTHALMICS	OP. -ANTI-ALLERGICS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Emadine, Alomide, and Alocril will be approved for pregnancy. Alomide will be approved for children under the age of 3.	ALAMAST ALOCRIL ALOMIDE ALREX azelastine BEPREVE EMADINE epinastine ketotifen LASTACAPT olopatadine 0.1% and 0.2%
	cromolyn PAZEO			
	OP. -ANTIBIOTICS- QUINOLONES		Trial and failure of a preferred agent greater than or equal to 5 days in the last 12 months will be required before approval can be given for a non-preferred agent. Azasite will be approved for pregnancy.	AZASITE BESIVANCE gatifloxacin IQUIX levofloxacin moxifloxacin 0.5% (BRAND IS PREFERRED) ZYMAR
	ciprofloxacin ofloxacin MOXEZA VIGAMOX*			
	OP. -ANTI-INFLAMMATORY		Trial and failure of ALL preferred agents each greater than or equal to 5 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	ACULAR/L5/PF (use preferred) ACUVAIL bromfenac 0.9% BROMSITE DUREZOL NEVENAC PROLENSA
	flurbiprofen diclofenac LOTEMAX ketorolac ILEVRO			
	OP. -BETA-BLOCKERS		Trial and failure of three (3) preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent. Betoptic S will be approved for those with heart and lung conditions.	BETIMOL BETOPTIC S ISTALOL
	betaxolol carteolol levobunolol metipranolol timolol			
	OP. -CARBONIC ANHYDRASE INHIBITOR		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	AZOPT
	dorzolamide			
OP. - COMBO PRODUCTS		Trial and failure of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.		
COMBIGAN dorzolamide/timolol SIMBRINZA				
OP. - DRY EYE AGENTS		Trial and failure of the preferred agent greater than or equal to 12 weeks will be required before approval can be given for the non-preferred agent.	RESTASIS MULTIDOSE (use preferred) XIIDRA	
RESTASIS				
OP. -PROSTAGLANDINS		Trial and failure of ALL preferred agents each greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	bimatoprost LUMIGAN 0.1% ZIOPTAN	
latanoprost TRAVATAN Z				
OP. -SYMPATHOMIMETICS		Trial of a preferred agent greater than or equal to 30 days in the last 12 months will be required before approval can be given for a non-preferred agent.	brimonidine 0.15% (BRAND IS PREFERRED)	
ALPHAGAN P 0.1% ALPHAGAN P 0.15%* brimonidine 0.2%				
OSTEOPOROSIS	BISPHOSPHONATES		Trial and failure of a preferred agent greater than or equal to 12 months will be required before approval can be given for a non-preferred agent. Fosamax liquid will be approved for clients that have difficulty swallowing.	risedronate ATELVIA FOSAMAX-D ibandronate TYMLOS
	alendronate			
NASAL CALCITONIN				
	calcitonin-salmon fortical			
OTIC	ANTIBIOTIC/STEROID COMBINATION			ciprofloxacin 0.2% (use preferred agent) CIPRO HC (use preferred agent) COLY-MYCIN S (use preferred agent) CORTISPORIN-TC (use preferred agent) FLUOCINOLONE ACET OIL 0.01% (use preferred agent) ofloxacin (use preferred agent)
	CIPRODEX Neo/Poly/Hc Suspension and Solution			
OVERACTIVE BLADDER	OVERACTIVE BLADDER AGENTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent. Oxytrol will be approved for clients that have an inability to swallow.	darifenacin GELNIQUE GEL 10% MYRBETRIQ OXYTROL DIS SANCTURA XR tolterodine/ER trospium VESICARE
	oxybutynin /ER TOVIAZ			

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, **Dosage Limitation List** (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at <http://wymedicaid.org> for additional criteria.

THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT YOUR PHARMACEUTICAL REPRESENTATIVE WITH ANY QUESTIONS</small>	
PAIN	LONG-ACTING C-III's		<p>Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>C-III's and C-IVs that are not included on the PDL and are available without prior authorization with the exception of Butrans (generic substitution is mandatory).</p> <p>Concurrent use of a narcotic and benzodiazepine will require prior authorization</p> <p>Fentanyl patches will require a prior authorization unless a client has a cancer diagnosis or previous treatment of at least a 10 day supply within the last 45 days</p> <p>**Butrans requires a trial of morphine sulfate ER or low dose trial of fentanyl patch.</p> <p>***Nucynta ER will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics.</p> <p>****In addition to above criteria, Embeda requires a diagnosis of drug/substance abuse.</p> <p>Belbuc: 1.2mg/day (1200mcg/day) Butrans: 20mcg, 1 strength at a time, 1 patch every 7 days Fentanyl: 50mcg, 1 strength at a time, 1 patch every 3 days Hysingla ER: 120mg/day Hydromorphone ER: 30mg/day Morphabond: 120mg/day Morphine ER: 120mg/day Methadone: Limited to 3 tablets per day Nucynta ER: 327mg/day Oxycontin: 80mg/day Oxymorphone ER: 40mg/day Xartemis XR: 80mg/day Xtampza ER: 80mg/day Zohydro ER: 120mg/day</p> <p>Clients will be limited to one long-acting narcotic at a time</p>	<p>AVINZA BELBUCA BUTRANS** EMBEDA**** fentanyl patch 37.5, 62.5, 87.5mg hydromorphone ER HYSINGLA ER (additional criteria applies) KADIAN 200mg (use preferred agent) METHADONE MORPHABOND morphine sulfate ER capsules (use preferred) NUCYNTEA ER*** oxymorphone ER OXYCONTIN XARTEMIS XR (additional criteria applies) XTAMPZA ER (additional criteria applies) ZOHYDRO ER (additional criteria applies)</p>	
	SHORT-ACTING C-III's				<p>Trial and failure of three (3) preferred agents greater than or equal to a 6 day supply in the last 90 days will be required before approval can be given for a non-preferred agent.</p> <p>*Nucynta will be allowed for diabetic peripheral neuropathy or clients with significant gastrointestinal concerns with other CII narcotics.</p> <p>Concurrent use of a narcotic and benzodiazepine will require prior authorization</p> <p>All short-acting narcotics, after 42 days of consecutive use of any combination of short-acting narcotics, will be limited to 4 tablets per day (liquids have specific dosing limits per medication - please refer to dosage limitation chart at www.wymedicaid.org)</p> <p>Clients will be limited to one short-acting narcotic at a time</p>
	C-III/C-IV AGENTS				<p>Trial and failure of a preferred agent(s) greater than or equal to a 14 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.</p> <p>Quantity and dosage limits apply (max 8 tabs/day).</p> <p>**Butrans will require a 14 day trial and failure of tramadol IR and a 14 day trial and failure of tramadol ER prior to approval</p>
PHOSPHATE BINDERS	PHOSPHATE BINDERS		Prior authorization required for non-preferred agents.	AURYXIA lanthanum PHOSLYRA sevelamer VELPHORO	
PROSTATE	5-ALPHA-REDUCTASE INHIBITORS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	dutasteride dutasteride/tamsulosin (use separate agents)	
	ALPHA BLOCKERS		Trial and failure of a preferred agent greater than or equal to a 30 day supply in the last 12 months will be required before approval can be given for a non-preferred agent.	alfuzosin dutasteride/tamsulosin (use separate agents) RAPAFLO	

WYOMING MEDICAID
Preferred Drug List (PDL) - March 14, 2018

Please refer to the Additional Therapeutic Criteria Chart, Dosage Limitation List (red font indicates quantity/dosage limits apply), and the Wyoming Medicaid Provider Manual at http://wymedicaid.org for additional criteria.				
THERAPEUTIC CLASS	PREFERRED AGENTS	PREFERRED AGENTS REQUIRING CLINICAL CRITERIA	CLINICAL CRITERIA	NON-PREFERRED AGENTS GENERIC MANDATORY POLICY APPLIES <small>THIS LIST IS NOT ALL INCLUSIVE PLEASE CONTACT OURSHE WITH ANY QUESTIONS</small>
PULMONARY ANTIHYPERTENSIVES	5-ALPHA-REDUCTASE INHIBITORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ADCIRCA REVATIO SUSPENSION sildenafil (Revatio A/B rated generic)		
	ENDOTHELIN RECEPTOR ANTAGONISTS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		LETAIRIS TRACLEER		
	PROSTACYCLINE VASODILATORS		Prior authorization required. Client must have a diagnosis of pulmonary hypertension with documented right-heart catheterization validating the diagnosis.	
		ORENITRAM		
	PROSTACYCLINE RECEPTOR AGONIST		Prior authorization required.	UPTRAVI (use preferred pulmonary HTN agent)
RESTLESS LEG SYNDROME	RESTLESS LEG SYNDROME		Client must have a diagnosis of Restless Leg Syndrome (RLS). Trial and failure of gabapentin greater than or equal to 60 days and a trial and failure of a dopamine agonist greater than or equal to 60 days in the last 12 months will be required before approval can be given for a non-preferred agent. *Neupro will be approved for clients with difficulty swallowing or for clients with a diagnosis of Parkinson's Disease.	HORIZANT NEUPRO*
		gabapentin pramipexole ropinirole		
SKELETAL MUSCLE RELAXANTS	MUSCLE RELAXANTS		Trial and failure of a preferred agent greater than or equal to a 14 day supply in the last 12 months, along with a medical diagnosis of muscle spasticity will be required before approval can be given for a non-preferred agent. Cyclobenzaprine will require a prior authorization for clients concurrently taking a tricyclic antidepressant.	carisoprodol chlorzoxazone cyclobenzaprine ER metaxalone methocarbamol orphenadrine tizanidine capsules (use preferred agent) Carisoprodol is limited to 84 tabs/365 days
	baclofen cyclobenzaprine tizanidine tablets			
ULCERATIVE COLITIS	IMMUNOMODULATORS		Client must have diagnosis of UC prior to approval of a preferred agent. To receive a non-preferred agent, client must have a diagnosis of UC and a 56-day trial and failure of the preferred agent.	REMICADE (additional criteria applies)
		HUMIRA		
UVEITIS	IMMUNOMODULATORS		Client must have diagnosis of non-infectious intermediate, posterior, and panuveitis in adult patients	
		HUMIRA		